Major yogurt brands, including Danone, Fage, and Chobani, have experienced significant sales growth, with Fage seeing a 16% jump and Chobani's zero-sugar products surging by 55% in the first three months of the year, catering to consumers managing weight or under GLP-1 treatment.
The Ozempic Revolution has negatively impacted the market value of food and drink companies while creating opportunities for those offering low-sugar, high-protein, and nutrient-rich products. Nestle and Danone introduced specialized yogurt and frozen food products targeting users of obesity treatments.
The global market for GLP-1 drugs is predicted to reach $105 billion by 2030, with an estimated 31.5 million users in the U.S. by 2035, leading to a significant impact on the global economy and the food industry, prompting food executives to seek advice from pharmaceutical companies on adapting to the increasing use of appetite-suppressing medications.
Nestle and Danone stocks have seen fluctuations this year.
This article was written in collaboration with Generative AI news company Alchemiq
Sources: Donga, Quartz, Fortune, Axios.